Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders

被引:180
作者
Hayashi, Teruo [1 ]
Tsai, Shang-Yi [2 ]
Mori, Tomohisa [2 ]
Fujimoto, Michiko [1 ]
Su, Tsung-Ping [2 ]
机构
[1] Natl Inst Drug Abuse, NIH, Cellular Stress Signaling Unit, Integrat Neurosci Branch, Baltimore, MD 21224 USA
[2] Natl Inst Drug Abuse, NIH, Cellular Pathobiol Sect, Integral Neurosci Branch, Baltimore, MD 21224 USA
关键词
ENDOPLASMIC-RETICULUM STRESS; OPEN CLINICAL-TRIAL; IMPROVED COGNITIVE IMPAIRMENTS; POSITRON-EMISSION-TOMOGRAPHY; IMPROVES NEGATIVE SYMPTOMS; UNFOLDED PROTEIN RESPONSE; UNIPOLAR MAJOR DEPRESSION; EMD; 57445; PANAMESINE; ALZHEIMERS-DISEASE; MOLECULAR-MECHANISMS;
D O I
10.1517/14728222.2011.560837
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Areas covered: Recent evidence that has shed light on sigma-1 receptor ligands, which may serve as a new class of antidepressants or neuroprotective agents. Sigma-1 receptors are novel ligand-operated molecular chaperones regulating signal transduction, ER stress, cellular redox, cellular survival and synaptogenesis. Selective sigma-1 receptor ligands exert rapid antidepressant-like, anxiolytic, antinociceptive and robust neuroprotective actions in preclinical studies. Recent studies that suggest that reactive oxygen species might play a role as signal integrators downstream of Sig-1Rs are also covered. Expert opinion: The advances in sigma receptor research in the last decade have begun to elucidate the intracellular signal cascades upstream and downstream of sigma-1 receptors. The novel ligand-operated properties of the sigma-1 receptor chaperone may enable interventions by which stress-related cellular systems can be pharmacologically controlled.
引用
收藏
页码:557 / 577
页数:21
相关论文
共 141 条
[1]   A single-site, double-blind, placebo-controlled, dose-ranging study of YKP10A - a putative, new antidepressant [J].
Amsterdam, JD ;
Brunswick, DJ ;
Hundert, M .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2002, 26 (7-8) :1333-1338
[2]   Anti-amnesic properties of (±)-PPCC, a novel sigma receptor ligand, on cognitive dysfunction induced by selective cholinergic lesion in rats [J].
Antonini, Vuokko ;
Prezzavento, Orazio ;
Coradazzi, Marino ;
Marrazzo, Agostino ;
Ronsisvalle, Simone ;
Arena, Emanuela ;
Leanza, Giampiero .
JOURNAL OF NEUROCHEMISTRY, 2009, 109 (03) :744-754
[3]   The sigma receptor as a ligand-regulated auxiliary potassium channel subunit [J].
Aydar, E ;
Palmer, CP ;
Klyachko, VA ;
Jackson, MB .
NEURON, 2002, 34 (03) :399-410
[4]   Targeting sigma-1 receptor with fluvoxamine ameliorates pressure-overload-induced hypertrophy and dysfunctions [J].
Bhuiyan, Md. Shenuarin ;
Tagashira, Hideaki ;
Shioda, Norifumi ;
Fukunaga, Kohji .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2010, 14 (10) :1009-1022
[5]   Dehydroepiandrosterone treatment of midlife dysthymia [J].
Bloch, M ;
Schmidt, PJ ;
Danaceau, MA ;
Adams, LF ;
Rubinow, DR .
BIOLOGICAL PSYCHIATRY, 1999, 45 (12) :1533-1541
[6]  
BORISON RL, 1991, PSYCHOPHARMACOL BULL, V27, P103
[7]   Aβ1-42 induces mild endoplasmic reticulum stress in an aggregation state-dependent manner [J].
Chafekar, Sidhartha M. ;
Hoozemans, Jeroen J. M. ;
Zwart, Rob ;
Baas, Frank ;
Scheper, Wiep .
ANTIOXIDANTS & REDOX SIGNALING, 2007, 9 (12) :2245-2254
[8]   AN EARLY PHASE-II CLINICAL-TRIAL OF BW234U IN THE TREATMENT OF ACUTE SCHIZOPHRENIA IN NEWLY ADMITTED PATIENTS [J].
CHOUINARD, G ;
ANNABLE, L .
PSYCHOPHARMACOLOGY, 1984, 84 (02) :282-284
[9]   Irreversible blockade of sigma-1 receptors by haloperidol and its metabolites in guinea pig brain and SH-SY5Y human neuroblastoma cells [J].
Cobos, Enrique J. ;
del Pozo, Esperanza ;
Baeyens, Jose M. .
JOURNAL OF NEUROCHEMISTRY, 2007, 102 (03) :812-825
[10]  
Csermely P, 2007, ADV EXP MED BIOL, V594, P55